Cumberland Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Cumberland Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	23.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Mar 07

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Jan 09

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Oct 02

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Nov 09

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Apr 21

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Feb 13

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Nov 19

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cumberland Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGS:CPIX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	39	-8	5	5	N/A
12/31/2023	40	-6	6	6	N/A
9/30/2023	39	-2	7	9	N/A
6/30/2023	41	-2	8	10	N/A
3/31/2023	40	-4	5	7	N/A
12/31/2022	42	-6	6	8	N/A
9/30/2022	41	-7	6	7	N/A
6/30/2022	38	-9	4	4	N/A
3/31/2022	37	-7	4	4	N/A
12/31/2021	36	-6	6	6	N/A
9/30/2021	38	-3	5	5	N/A
6/30/2021	39	-3	5	6	N/A
3/31/2021	40	-5	5	6	N/A
12/31/2020	37	-7	3	5	N/A
9/30/2020	36	-8	3	5	N/A
6/30/2020	34	-10	4	5	N/A
3/31/2020	34	-10	3	4	N/A
12/31/2019	34	-9	2	3	N/A
9/30/2019	39	-8	3	6	N/A
6/30/2019	40	-6	0	4	N/A
3/31/2019	41	-6	-2	2	N/A
12/31/2018	29	-11	-1	3	N/A
9/30/2018	39	-6	-3	-1	N/A
6/30/2018	42	-5	0	2	N/A
3/31/2018	40	-9	-3	-2	N/A
12/31/2017	41	-8	N/A	-1	N/A
9/30/2017	39	-8	N/A	1	N/A
6/30/2017	36	-7	N/A	0	N/A
3/31/2017	35	-2	N/A	1	N/A
12/31/2016	33	-1	N/A	1	N/A
9/30/2016	32	0	N/A	1	N/A
6/30/2016	31	0	N/A	1	N/A
3/31/2016	33	0	N/A	4	N/A
12/31/2015	34	1	N/A	6	N/A
9/30/2015	35	1	N/A	7	N/A
6/30/2015	37	2	N/A	9	N/A
3/31/2015	37	2	N/A	8	N/A
12/31/2014	37	2	N/A	7	N/A
9/30/2014	36	0	N/A	4	N/A
6/30/2014	33	-1	N/A	1	N/A
3/31/2014	30	-3	N/A	0	N/A
12/31/2013	32	-2	N/A	1	N/A
9/30/2013	38	1	N/A	3	N/A
6/30/2013	44	4	N/A	6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CPIX's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if CPIX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CPIX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CPIX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CPIX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CPIX's Return on Equity is forecast to be high in 3 years time

Cumberland Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus forecasts updated

Consensus EPS estimates increase to -US$0.18

Analysts update estimates

Analysts lower EPS estimates to -US$0.37

Recent updates

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024

Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.

New minor risk - Share price stability

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022)

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023

Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age

New minor risk - Share price stability

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023

Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs

Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary Fibrosis

U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for Caldolor

First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022)

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021)

Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors

Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug Administration

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021)

Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Inc. Announces Executive Changes

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle East

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022

Now 22% undervalued

Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.

Checking In On Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor®

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020)

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Consensus forecasts updated

Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020)

Cumberland Pharmaceuticals Inc.(NasdaqGS:CPIX) dropped from Russell Microcap Growth Index

Cumberland Pharmaceuticals Inc. Releases a Series of Case Reports Describing the Effectiveness of Vibativ® (Telavancin) in Treating Secondary Bacterial Infections in COVID-19 Patients

Consensus EPS estimates increase to -US$0.18

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.43 loss per share (vs US$0.23 loss in FY 2019)

Revenue beats expectations

Cumberland Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 09, 2021

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

New 90-day high: US$3.31

New 90-day high: US$3.22

Analysts update estimates

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Cumberland Pharmaceuticals Inc. Announces the Launch of Reditrex® (Methotrexate) Injection

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.083 loss per share

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.083 loss per share

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Cumberland Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 10, 2020